Eli Lilly and Co., of Indianapolis, reported results from its phase III study of Cyramza (ramucirumab) in combination with paclitaxel in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma, showing that the addition of ramucirumab showed a statistically significant improvement in median overall survival, meeting the primary endpoint.